<strong>Nurs<strong>in</strong>g</strong> <strong>Care</strong> <strong>of</strong> <strong>Dyspnea</strong>: <strong>The</strong> <strong>6th</strong> <strong>Vital</strong> <strong>Sign</strong> <strong>in</strong> <strong>Individuals</strong> <strong>with</strong> Chronic Obstructive Pulmonary Disease (COPD)Table 1: COPD Severity and Symptom DescriptorsDiseaseSeverityPulmonaryFunctionChanges <strong>in</strong> Level <strong>of</strong>Activity (O’Donnell etal., 2003)Stable Cl<strong>in</strong>icalSymptomsUnstable/AcuteCl<strong>in</strong>ical SymptomsEvidence <strong>of</strong> AcuteRespiratory FailureMild(stage I)Moderate(stage II)Severe(stage III)FEV 160 – 79%predictedFEV 1 /FVC< 70%FEV 140 – 59%predictedFEV 1 /FVC< 70%FEV 1< 40%predictedFEV 1 /FVC< 70%<strong>Dyspnea</strong> from COPDwhen hurry<strong>in</strong>g on thelevel or walk<strong>in</strong>g up aslight hill*DYSPNEA SCORE(MRC 2)<strong>Dyspnea</strong> from COPDcaus<strong>in</strong>g patient to stopafter walk<strong>in</strong>g about100 m (or after a fewm<strong>in</strong>utes) on the level*DYSPNEA SCORE(MRC 3-4)<strong>Dyspnea</strong> from COPDresult<strong>in</strong>g <strong>in</strong> the patienttoo breathless to leavethe house, orbreathlessness afterundress<strong>in</strong>g, or thepresence <strong>of</strong> chronicrespiratory failure orcl<strong>in</strong>ical signs <strong>of</strong> rightheart failure*DYSPNEA SCORE(MRC 5)1.Respiratory rate <strong>with</strong><strong>in</strong> normal limits(RR 16-28)2.Chest auscultation: breath soundsreduced, may or may not have endexpiratory wheeze and/or crackles.3.Adequate <strong>in</strong>spiratory depth andchest wall expansion, may have barrelshaped chest.4.M<strong>in</strong>imal or no respiratory accessorymuscle use.5.May have clear or white sputum.6.Daily cough.7.May not have compla<strong>in</strong>ts <strong>of</strong> fatigue.1.Respiratory rate above normal limits.2.Chest auscultation: breath soundsreduced, may or may not have endexpiratory wheeze and/or crackles.3.Adequate chest wall expansion.4.M<strong>in</strong>imal or moderate accessorymuscle use.5.May have clear or white sputum.6.Daily cough.7.Fatigue <strong>of</strong>ten present.1.Respiratory rate outside normal limits.2.Chest auscultation: air entry distant,may or may not have end expiratorywheeze and/or crackles.3.Adequate chest wall expansion.4.Moderate accessory muscle use.5.May have clear or white sputum.6.Daily cough.7.Fatigue usually present.Compla<strong>in</strong>ts <strong>of</strong> <strong>in</strong>creas<strong>in</strong>glevel <strong>of</strong> dyspnea1. Respiratory rate mayor may not be <strong>with</strong><strong>in</strong>normal limits.2. Chest auscultation:breath soundsreduced, may or maynot have endexpiratory wheezeand/or crackles.3. May have shallow<strong>in</strong>spiratory depth<strong>with</strong> reduced chestwall expansion.4. Respiratory accessorymuscle use.5. Sputum change:yellow/green/purulent/thick and/or<strong>in</strong>creased amount.6. Increased coughseverity.7. Progressive fatigue.8. Potential presence <strong>of</strong>peripheral and/orcentral cyanosis.Pulmonary: accessory muscleuse, compla<strong>in</strong>ts <strong>of</strong> worsen<strong>in</strong>gdyspnea, compla<strong>in</strong>ts <strong>of</strong>impend<strong>in</strong>g doom.PaO 2 < 60 mmHg on room airPaCO 2 > 50 mmHgArterial pH < 7.28S P O 2 < 88 % [Although pulseoximetry is a valuable tool <strong>in</strong>many disease processes, it isnot a reliable <strong>in</strong>dicator <strong>of</strong>dypnea severity <strong>in</strong> <strong>in</strong>dividuals<strong>with</strong> COPD.]Neuro: Restlessness, agitation,headache, disorientation,seizures, muscle twitch<strong>in</strong>g,decreased level <strong>of</strong> consiousness.CVS: heart rate, hypertension(early sign), hypotension (latesign), chest pa<strong>in</strong>, dysrhythmias.Renal: ur<strong>in</strong>ary output,peripheral edema.GI: bowel sounds, nauseaand vomit<strong>in</strong>g, abdom<strong>in</strong>aldistention, bleed<strong>in</strong>g.Sk<strong>in</strong>: cool, clammy, pale, capillary refill.* Perception <strong>of</strong> dyspnea is <strong>in</strong>dividualized and may vary from the usual scores above. RNAO Guidel<strong>in</strong>e Development Panel, 200526
<strong>Nurs<strong>in</strong>g</strong> Best Practice Guidel<strong>in</strong>eRecommendation 1.3:Every adult <strong>with</strong> dyspnea who has a history <strong>of</strong> smok<strong>in</strong>g and is over the age <strong>of</strong> 40 should be screenedto identify those most likely to be affected by COPD. As part <strong>of</strong> the basic dyspnea assessment, nursesshould ask every patient:■ Do you have progressive activity-related shortness <strong>of</strong> breath?■ Do you have a persistent cough and sputum production?■ Do you experience frequent respiratory tract <strong>in</strong>fections? (Level <strong>of</strong> Evidence =IV)Recommendation 1.4:For patients who have a history <strong>of</strong> smok<strong>in</strong>g and are over the age <strong>of</strong> 40, nurses should advocate forspirometric test<strong>in</strong>g to establish early diagnosis <strong>in</strong> at risk <strong>in</strong>dividuals. (Level <strong>of</strong> Evidence =IV)Discussion <strong>of</strong> Evidence:Most <strong>in</strong>dividuals <strong>with</strong> COPD are not diagnosed until the disease is well advanced. Despite the lack <strong>of</strong>evidence support<strong>in</strong>g mass screen<strong>in</strong>g for COPD among asymptomatic smokers, the Canadian ThoracicSociety (O’Donnell et al., 2003) does recommend perform<strong>in</strong>g targeted spirometric test<strong>in</strong>g to establish earlydiagnosis <strong>in</strong> at risk <strong>in</strong>dividuals. <strong>The</strong> above cl<strong>in</strong>ical <strong>in</strong>formation will help identify those <strong>in</strong>dividualsconsidered potentially at risk for the development <strong>of</strong> COPD related to smok<strong>in</strong>g. Nurses are encouraged toadvocate for early screen<strong>in</strong>g for those patients who have a history <strong>of</strong> smok<strong>in</strong>g and are over the age <strong>of</strong> 40(DeJong & Veltman, 2004).Enright and Crapo (2000) <strong>in</strong> a recent review question the number <strong>of</strong> false-positive and false-negative rates<strong>of</strong> <strong>of</strong>fice spirometry for early recognition and diagnosis <strong>of</strong> COPD <strong>in</strong> cigarette smokers. A consensusstatement from the National Lung Health Education Program recommends the development, validation,and implemention <strong>of</strong> <strong>of</strong>fice spirometry for the purpose <strong>of</strong> early diagnosis <strong>in</strong> ‘at risk’ <strong>in</strong>dividuals <strong>in</strong> theprimary care sett<strong>in</strong>g (Ferguson, Enright, Buist & Higg<strong>in</strong>s, 2000).27